-
公开(公告)号：US20230112866A1
公开(公告)日：2023-04-13
申请号：US17910768
申请日：2021-03-12
发明人： Daniel SERIE , Klaus LINDPAINTNER
IPC分类号： G01N33/68 , C12Q1/6872 , G01N33/574
摘要： Set forth herein are methods useful for identifying disease biomarkers, particularly for diseases such as clear cell renal cell carcinoma (ccRCC). In some examples, the methods set forth herein are useful for monitoring the prognosis of patients having a disease such as ccRCC.
-
公开(公告)号：US11623955B2
公开(公告)日：2023-04-11
申请号：US16748695
申请日：2020-01-21
申请人： Compugen Ltd.
发明人： Mark White , Sandeep Kumar , Christopher Chan , Spencer Liang , Lance Stapleton , Andrew W. Drake , Yosi Gozlan , Ilan Vaknin , Shirley Sameah-Greenwald , Liat Dassa , Zohar Tiran , Gad S. Cojocaru , Leonard Presta , Richard Theolis
IPC分类号： C07K16/28 , C07K7/06 , G01N33/574 , C12N15/113
摘要： The present invention is directed to anti-PVRIG antibodies and methods of using same.
-
13.发明授权公开(公告)号：US11623014B2
公开(公告)日：2023-04-11
申请号：US17127265
申请日：2020-12-18
发明人： Martin Behe , Roger Schibli
IPC分类号： A61K51/08 , A61K38/22 , C07K14/575 , C07K14/595 , C07B59/00 , C07K1/13 , C07K7/08 , G01N33/574
摘要： A gastrin analogue shows high uptake in CCK-2 receptor positive tumors and simultaneously a very low accumulation in the kidneys. This is achieved by a mini-gastrin analogue PP-F11 having the formula: PP-F11-X-DGlu-DGlu-DGlu-DGlu-DGlu-DGlu-Ala-Tyr-Gly-Trp-Y-Asp-Phe-NH2, wherein Y is an amino acid replacing methionine and X is a chemical group attached to the peptide for diagnostic and/or therapeutic intervention at CCK-2 receptor relevant diseases. Very suitable compounds with respect to a high tumor to kidney ratio are mini-gastrin analogues with six D-glutamic acids or six glutamines. These compounds still possess a methionine which can be oxidized easily which is a disadvantage for clinical application under GMP due to the forms which may occur. The elimination of the methionine leads to a lower affinity to oxidation which in general favors the tumor-kidney-ratio. Ideally, the methionine is replaced by norleucine. This PP-F11N mini gastrin exhibits currently the best tumor-kidney-ratio and is the most promising candidate.
-
公开(公告)号：US11618774B2
公开(公告)日：2023-04-04
申请号：US17576714
申请日：2022-01-14
发明人： Colette Song , Oliver Schoor , Jens Fritsche , Toni Weinschenk , Harpreet Singh
IPC分类号： A61K39/00 , C07K14/47 , A61P35/00 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/10 , C12N15/115 , G01N33/574 , A61K35/17 , C07K7/06 , C07K14/54 , A61K38/00
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20230099264A1
公开(公告)日：2023-03-30
申请号：US17800728
申请日：2021-02-17
发明人： Jong Kuk Park , Hong Duck Um , Sang Gu Hwang , Jie Young Song , Jeong Hyun Cho
IPC分类号： G01N33/574
摘要： The present invention provides a method for providing information for diagnosis of metastasis of radiotherapy-treated lung cancer, the method comprising the steps of: (a) measuring an expression level of receptor-interacting protein kinase 1 (RIP1) in a sample from a lung cancer patient who has undergone radiotherapy; (b) measuring an expression level of RIP1 in a normal control sample; and (c) comparing the expression levels of step (a) and step (b).
-
公开(公告)号：US20230094286A1
公开(公告)日：2023-03-30
申请号：US17929344
申请日：2022-09-02
发明人： Colette SONG , Oliver SCHOOR , Jens FRITSCHE , Toni WEINSCHENK , Harpreet SINGH
IPC分类号： C07K14/47 , A61P35/00 , A61K39/00 , C07K14/725 , C07K14/74 , C07K16/28 , C07K16/30 , C12N5/0783 , C12N15/10 , C12N15/115 , G01N33/574 , A61K35/17 , C07K7/06 , C07K14/54
摘要： The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
-
公开(公告)号：US20230089465A1
公开(公告)日：2023-03-23
申请号：US17936006
申请日：2022-09-28
申请人： The United States of America,as represented by the Secretary,Department of Health and Human Services
发明人： Paul F. Robbins , Steven A. Rosenberg , Xin Yao
IPC分类号： C07K14/725 , A61K38/17 , C07K14/73 , A61K39/00 , C07K16/00 , C07K16/28 , G01N33/574
摘要： The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.
-
公开(公告)号：US20230085980A1
公开(公告)日：2023-03-23
申请号：US17756689
申请日：2020-02-21
申请人： Tianjin University
发明人： Lizhi Mi , Xingxing Wang , Peng Liu , Xiaohong Qin , Zhiqun Shang
IPC分类号： A61K49/00 , G01N33/574
摘要： The present application is directed to a theranostic probe and its use for targeting and/or labeling the EGFR kinase and/or the cells expressing EGFR or its family members.
-
公开(公告)号：US11607465B2
公开(公告)日：2023-03-21
申请号：US16934881
申请日：2020-07-21
发明人： Gabriela Chiosis , Naga Vara Kishore Pillarsetty , Jason S. Lewis , Steven M. Larson , Tony Taldone , Mary L. Alpaugh , Erica M. Gomes-DaGama
IPC分类号： A61K51/04 , G01N33/50 , G01N33/574 , A61K31/52
摘要： This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.
-
公开(公告)号：US20230085564A1
公开(公告)日：2023-03-16
申请号：US17932124
申请日：2022-09-14
申请人： OmniSeq, Inc.
发明人： Carl Morrison , Sarabjot Pabla , Jeffrey Conroy , Mary Nesline , Mark Gardner , Ji He , Sean Glenn
IPC分类号： G16B40/00 , G16B5/00 , G16B20/00 , G01N33/574 , C07K16/28 , C12Q1/6886 , G16B20/20 , G16B5/20 , G16B20/40
摘要： A method for generating an immune score, the method comprising the steps of: (i) determining a qualitative and/or quantitative assessment of tumor infiltrating lymphocytes in a sample; (ii) determining a qualitative and/or quantitative assessment of T-cell receptor signaling in the sample; (iii) determining a qualitative and/or quantitative assessment of mutation burden in the sample; (iv) generating, using a predictive algorithm, an immune score based on the determined qualitative and/or quantitative assessment of tumor infiltrating lymphocytes, the determined qualitative and/or quantitative assessment of T-cell receptor signaling, and the determined qualitative and/or quantitative assessment of mutation burden.
-
-
-
-
-
-
-
-
-
搜索结果
16744 条记录 (耗时 0.343 秒)